Fundraising Fox
/Companies
Sign in

XyloCor Therapeutics

Malvern, US · Delaware corporation · 5 known investors

Find your way into XyloCor Therapeutics

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.

BiotechHealthtechMedical Devices

Founders & leadership

RCRonald Crystal
Ronald CrystalCo-founder
TRTodd Rosengart
Todd RosengartCo-founder
JTJohn Tucker
John TuckerPresident and Chief Executive Officer
AG
Albert GianchettiExecutive

Board

GBGlenn Batchelder
Glenn BatchelderChairmanVenture Partner at Pivotal Life Sciences
JC
James CohenBoard director

Investors · 5

Fountain Healthcare Partners✓ confirmed by XyloCor TherapeuticsDublin · $10.8M – $16.2M

How we know: the company's own site · Not right? Tell us

Jeito Capitallisted by Jeito CapitalParis

How we know: Jeito Capital's portfolio page · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · the VCSheet dataset · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$21.4M disclosed across 6 of 7 rounds · 2016–2025

▶$4MraisedJan 2021 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Fouad Azzam, Ph.D.Director
  • Aidan KingDirector
  • Michael F. Powell, Ph.D.Director
  • Todd K. Rosengart, M.D.Director
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
Amount sold
$4M
First sale
Jan 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.8MraisedOct 2018 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Todd RosengartDirector
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
  • James CohenDirector
Offering amount
$16.8M
Amount sold
$16.8M
First sale
Oct 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$200KraisedJul 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Glenn BatchelderDirector
  • James CohenDirector
  • Todd RosengartDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$200K
Amount sold
$200K
First sale
Jul 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60KraisedMar 2018 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James CohenDirector
  • Glenn BatchelderDirector
  • Albert GianchettiExecutive Officer, Director
  • Todd RosengartDirector
Offering amount
$150K
Amount sold
$60K
First sale
Mar 2018
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100KraisedDec 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Todd RosengartDirector
  • Glenn BatchelderDirector
  • James CohenDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$100K
Amount sold
$100K
First sale
Nov 2017
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250KraisedNov 2016 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Glenn BatchelderDirector
  • James CohenDirector
  • Albert GianchettiExecutive Officer, Director
Offering amount
$1M
Amount sold
$250K
First sale
Nov 2016
Incorporated
Corporation, Delaware, 2013
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 5

by search overlap
Capricor Therapeutics15 shared keywordsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.
CeleCor Therapeutics13 shared keywordsCelecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.
Arecor12 shared keywordsAreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.
DalCor www.dalcorpharma.com7 shared keywordsDalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
AliveCor6 shared keywordsAliveCor develops digital health solutions focused on cardiovascular care, serving employers and healthcare payers seeking enterprise heart health platforms.

Companies competing with XyloCor Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2023$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does XyloCor Therapeutics do?
XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.
Who founded XyloCor Therapeutics?
XyloCor Therapeutics was founded by Ronald Crystal, Todd Rosengart.
Who are XyloCor Therapeutics's investors?
XyloCor Therapeutics's investors include Lumira Ventures, Fountain Healthcare Partners, Jeito Capital, Longwood Fund, Sofinnova Ventures.
How much funding has XyloCor Therapeutics raised?
XyloCor Therapeutics has disclosed $21.4M raised across 6 of its 7 known rounds.
Where is XyloCor Therapeutics headquartered?
XyloCor Therapeutics is headquartered in Malvern, US.